Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Urinary Bladder Neoplasms 5Breast Neoplasms 3Urothelial Cancer 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 149Docetaxel 139Paclitaxel 127Trastuzumab 120Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × vinflunine × Clear all
NCT01095003 2022-04-28

Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

Pierre Fabre Medicament

Phase 3 Completed
770 enrolled 13 charts
Breast

Breast Neoplasms

NCT01091168 2019-09-16

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

Pierre Fabre Medicament

Phase 3 Completed
594 enrolled 11 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01953003 2019-05-02

Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Pierre Fabre Medicament

Phase 3 Completed
112 enrolled 11 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡